Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02074865
Other study ID # 2012-11 ChARLI
Secondary ID
Status Recruiting
Phase N/A
First received July 10, 2013
Last updated February 25, 2014
Start date September 2012

Study information

Verified date February 2014
Source Institut Pasteur
Contact Didier Guillemot, MD, PhD
Phone 0145688301
Email didier.guillemot@pasteur.fr
Is FDA regulated No
Health authority Madagascar: Ministry of Health
Study type Observational

Clinical Trial Summary

The main challenge of the ChARLI program is to assess the clinical burden of severe neonatal and childhood bacterial infections in low-income countries,in particular those caused by antibiotic resistant bacteria. This program will address both healthcare associated, as well as community acquired infections. Beside its main challenge, the ChARLI program will also allow the assessment of the economic burden of these infections, the improvement of their medical care and then ultimately help to set public health interventions and guide public health measures necessary to combat bacterial infections and bacterial resistance in children. It will also lead to set up more basic research investigation to better understand how pathogenic and epidemic may be the resistant clones in these countries and to experiment innovative strategies devoted to prevent these infections.

In order to achieve these objectives, an international paediatric cohort will be created, and monitored a platform. This will be done first within the Institut Pasteur International Network (IPIN) and possibly extended in some others low income countries where the IPIN has no center. This constituted initiative will represent the first international pediatric program of its size to be located in low-income countries and specifically focusing severe bacterial infections and bacterial resistance to antibiotics


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date
Est. primary completion date March 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A to 3 Days
Eligibility Inclusion Criteria:

- Neonate born to parents living in the study zone of a participating country

- Parents of the neonate not intending to move away from the study zone during the follow-up period

- Legal guardians of the neonate informed about the way in which the study is to be carried out and about the collection of biological samples

- Legal guardians of the neonate having no objection to the collection of biological samples

- Authorisation from at least one of the legal guardians of the child, in the form of a signed informed consent form.

Exclusion Criteria:

- Stillborn neonate

- Parents of the neonate living outside the study zone of a participating country

- Neonate born to parents planning to move away from the study zone of a participating country during the follow-up period

- At least one of the legal guardians of the neonate not informed about the study or about the collection of biological samples

- At least one of the legal guardians of the neonate opposed to the collection of biological samples.

- Neonate already participating in another biomedical study.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Biological:
biological samples


Locations

Country Name City State
Madagascar institut pasteur in Madagascar Antananarivo

Sponsors (3)

Lead Sponsor Collaborator
Institut Pasteur department of International cooperation of Monaco (funding), Institut Pasteur in Madagascar (subject recruitment)

Country where clinical trial is conducted

Madagascar, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of infections with bacteria resistant to antibiotics in neonates and young children (up to 18 months of age). 27 months No
Secondary Bacterial aetiology of neonatal infection in low income countries and its resistance 27 months No
Secondary Identification of factors responsible of the dissemination and transmission of multiresistant resistant bacteria in low incomes countries 27 months No
See also
  Status Clinical Trial Phase
Completed NCT03726216 - Xydalba Utilization Registry in France
Completed NCT03605498 - OR PathTrac (Tracking Intra-operative Bacterial Transmission)
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT01932034 - Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software N/A
Completed NCT01689207 - To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) Phase 1
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Not yet recruiting NCT01159470 - The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children N/A
Completed NCT00983255 - Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) Phase 1
Completed NCT00678106 - Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections Phase 1
Completed NCT00799591 - French Study In ICU Patients Treated With Tigecycline N/A
Completed NCT01074775 - Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection N/A
Completed NCT00478855 - Tazocin Intervention Study Phase 4
Terminated NCT00431028 - Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery Phase 1/Phase 2
Not yet recruiting NCT03634904 - Serum Ceftazidime Concentrations in Hemodialysis Patients N/A
Recruiting NCT05684705 - Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 Phase 1
Recruiting NCT03858387 - PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
Enrolling by invitation NCT04764058 - Efficacy and Safety of Colistin Based Antibiotic Therapy Phase 1/Phase 2
Recruiting NCT06319235 - Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® Phase 1/Phase 2
Completed NCT03332732 - VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers Phase 1

External Links